Kumar S, Das A
Chin J Integr Med. 2023; 30(1):42-51.
PMID: 37118529
DOI: 10.1007/s11655-023-3694-0.
Lin K, Wu C, Mokgautsi N, Lawal B, Wu C, Wu A
Am J Cancer Res. 2023; 13(3):1004-1025.
PMID: 37034220
PMC: 10077027.
Peng G, Chi H, Gao X, Zhang J, Song G, Xie X
Front Genet. 2022; 13:1010044.
PMID: 36406133
PMC: 9672384.
DOI: 10.3389/fgene.2022.1010044.
Minesaki A, Kai K, Kuratomi Y, Aishima S
BMC Cancer. 2021; 21(1):973.
PMID: 34461859
PMC: 8406956.
DOI: 10.1186/s12885-021-08715-6.
Chen S, Krinsky A, Woolaver R, Wang X, Chen Z, Wang J
Mol Carcinog. 2020; 59(7):766-774.
PMID: 32017286
PMC: 7282929.
DOI: 10.1002/mc.23162.
The role of the innate and adaptive immune response in HPV-associated oropharyngeal squamous cell carcinoma.
Subbarayan R, Arnold L, Gomez J, Thomas S
Laryngoscope Investig Otolaryngol. 2019; 4(5):508-512.
PMID: 31637294
PMC: 6793605.
DOI: 10.1002/lio2.300.
Checkpoint immunotherapy in head and neck cancers.
Zolkind P, Uppaluri R
Cancer Metastasis Rev. 2017; 36(3):475-489.
PMID: 28836124
PMC: 7694874.
DOI: 10.1007/s10555-017-9694-9.
Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.
Johnson S, Levingston C, Young M
Anticancer Res. 2016; 36(7):3261-70.
PMID: 27354582
PMC: 5032137.
A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Zandberg D, Rollins S, Goloubeva O, Morales R, Tan M, Taylor R
Cancer Immunol Immunother. 2014; 64(3):367-79.
PMID: 25537079
PMC: 4381442.
DOI: 10.1007/s00262-014-1640-x.
Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma.
Russell S, Angell T, Lechner M, Liebertz D, Correa A, Sinha U
Head Neck Oncol. 2014; 5(3):24.
PMID: 24723971
PMC: 3979926.
Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer.
Johnson S, De Costa A, Young M
Cancers (Basel). 2014; 6(2):756-70.
PMID: 24698959
PMC: 4074802.
DOI: 10.3390/cancers6020756.
Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.
Andersson B, Lewin F, Lundgren J, Nilsson M, Rutqvist L, Lofgren S
J Cancer Res Clin Oncol. 2014; 140(3):515-9.
PMID: 24481866
DOI: 10.1007/s00432-014-1592-8.
Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients.
Green V, Michno A, Greenman J, Stafford N
Results Immunol. 2013; 2:1-6.
PMID: 24371560
PMC: 3862341.
DOI: 10.1016/j.rinim.2011.12.001.
Lentiviral vector-based therapy in head and neck cancer (Review).
Upreti D, Pathak A, Kung S
Oncol Lett. 2013; 7(1):3-9.
PMID: 24348811
PMC: 3861563.
DOI: 10.3892/ol.2013.1652.
Increased frequency and suppressive activity of CD127(low/-) regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement.
Drennan S, Stafford N, Greenman J, Green V
Immunology. 2013; 140(3):335-43.
PMID: 23826668
PMC: 3800438.
DOI: 10.1111/imm.12144.
Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer.
Judd N, Allen C, Winkler A, Uppaluri R
Otolaryngol Head Neck Surg. 2012; 147(3):493-500.
PMID: 22434099
PMC: 6346425.
DOI: 10.1177/0194599812442037.
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
Voskens C, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M
Head Neck. 2012; 34(12):1734-46.
PMID: 22287423
PMC: 3725741.
DOI: 10.1002/hed.22004.
A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.
Whiteside T, Butterfield L, Naylor P, Egan J, Hadden J, Baltzer L
Cancer Immunol Immunother. 2011; 61(6):783-8.
PMID: 22109700
PMC: 3721338.
DOI: 10.1007/s00262-011-1136-x.
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.
Berinstein N, Wolf G, Naylor P, Baltzer L, Egan J, Brandwein H
Cancer Immunol Immunother. 2011; 61(6):771-82.
PMID: 22057678
PMC: 5300054.
DOI: 10.1007/s00262-011-1134-z.
USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics.
Russell S, Lechner M, Gong L, Megiel C, Liebertz D, Masood R
Oral Oncol. 2011; 47(9):810-7.
PMID: 21719345
PMC: 3164740.
DOI: 10.1016/j.oraloncology.2011.05.015.